Monoclonal antibody (B cell depleting agent)

This page covers all Monoclonal antibody (B cell depleting agent) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD20, CD28/B7.

Targets

CD20 · CD28/B7

Phase 3 pipeline (1)

• RTX infusions · Frédéric A. Houssiau, MD, PhD · Immunology
  RTX (rituximab) is a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen on their surface.

Phase 2 pipeline (1)

• Atacicept: with loading dose · EMD Serono · Immunology
  CD28/B7 costimulation blockade

Patent intelligence

• b cell depleting agent patent landscape — aggregated cliff calendar, attackable patents, originator estates